IMEXHS LIMITED — AGM Information 2024

Apr 22, 2024

23 April 2024

ASX ANNOUNCEMENT

2024 Annual General Meeting – Chairman and CEO Addresses

In accordance with ASX Listing Rule 3.13, attached are the Chairman and CEO Addresses together with the presentation slides, which will be delivered at the IMEXHS Limited Annual General Meeting commencing at 11.00 am today.

Authorised for release by the Board of IMEXHS Limited.

-ENDS-

For more information, please contact:

Business Inquiries

Reena Minhas, CFO & Company Secretary

E: enquiries@imexhs.com.au

T: +61 (0)438 481 139

About IMEXHS

IMEXHS Limited (ASX: IME) is an innovative provider of medical imaging software and radiology services in 18 countries including Colombia, the US and Australia. Founded in 2012, IMEXHS develops software as a service (SaaS) imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are completely cloud-based, vendor neutral and zero footprint, with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that enhances patient outcomes. For more information, visit www.imexhs.com

IMEXHS Limited Annual General Meeting 23 April 2024

Chairman’s Address

This AGM is on much earlier in the year than we would normally hold it. We did so because of the opportunity to align with the need to hold a meeting to approve the placement to directors and hold the AGM at the same time. That does however create some issues as we seek to provide an update on the business.

Shareholders are probably feeling they are receiving more economic commentary than they need so I will try to limit such comments I make to those most specific to our company.

2023 continued to be challenging one for markets around the world with Central Banks pressing on with interest rate increases well into the year. By year end we saw inflation rates responding in the USA, England, Canada, Australia and the Eurozone and discussion at least of an easing of interest rates expected in 2024. In the central American economies core to our business, Colombia continued to have an inflation rate of circa 10% at year end and quite punishing interest rates. In other key markets in Latin America inflation rates are mid-single digits. In 2023, for most Central American economies a key feature has been strong currencies driven by abating inflation and high interest rates. The recent data is showing inflation in the USA being a touch higher than expected and consequently the associated likelihood that interest rate cuts may be less and later than we might have expected just three months ago.

Our policy of pricing our software in USD, where possible and that is now in most new contracts, continues to see growth in the share of USD denominated revenue. For 2023 that represented 45% of revenue versus 31% in 2022.

For IMEXHS, 2023 has been all about pursuing organic growth with more focused geographic markets off a reduced cost base in line with the plan laid out for the year. The company has delivered strong sales performance for both software and radiology and we enter 2024 well positioned to deliver revenue growth and earnings. Interestingly a significant share of our increase in sales has come from additional services and capability for existing clients across both software and radiology.

Sales, although inherently lumpy, were on plan throughout the year. There is a significant portion of that sales value that is at an early stage of being a newly started contract in ramp up phase or yet to be installed and billing. These elements will drive increased revenue from the early months of 2024. Pleasingly the reported 2H FY23 results saw a considerable step-up of 42% of revenue year over year and 23% up vs 1H FY23.

While the software business has performed largely to plan in sales, revenue and profitability the radiology business has suffered from two key issues; systemically slow receipts, driven by the high interest rate regime and individual client profitability created by an inflation drag on costs and some

difficulty in passing on those costs. That said, the hospital out-sourced business model for radiology remains entirely relevant and growing.

Our management team has a clear pathway to improving radiology client profitability and is well focused on solving the slow payment behaviour which has caused our working capital to rise significantly across the year.

Capital Raise

Subsequent to our 2023 Annual results announcement the company undertook a Capital Raise in March of this year via a Placement of $1.25m supported by new and existing institutional investors.

A Conditional placement to directors and their associated entities was also made to raise $0.25m, subject to approval by shareholders at this meeting.

Shares under the Placement and Conditional Placement are or will be issued at A$0.55 representing a 15.4% discount to the last closing price of A$0.65 on 6 March 2024 and a 13% discount to the 5-day VWAP.

The net proceeds of the Offer will be used to strengthen the Company’s balance sheet and drive growth with a focus on supporting new and future contracts.

Plan and Outlook

The company has started 2024 in a strong position for growth from the perspective of a strong Q4 in 2023, revenue moving in the short term from not yet billing into billing status and the value of earlystage contracts ramping up towards the scale we expect. We also start 2024 with a strong pipeline of opportunities. We are clear about some issues to fix and are confident we have the plan to do that satisfactorily and work is underway to improve radiology profitability.

Importantly we expect significant value for the company will come from the program of software enhancements developed over the last 15 months to create a New Value Proposition (NVP). The enhancements will benefit all clients but more particularly larger more complex hospitals and higher value opportunities. The NVP provides improvements in service and resilience and reducing help desk requirements, usability, functionality, integration, security, access to AI and post processing tools and speed of implementation.

While the early stage of the New Value Proposition is now in trial the full suite will not begin to be rolled out until Q4. Each of the elements of the NVP represents real client benefits versus our competitor universe. Significant improvements in service delivery, resilience and reducing help desk support will be delivered earlier and from this quarter. This significant advance in our software development is being undertaken with a modest increase in software capex compared to the prior period.

Ongoing growth will continue to place demands on working capital, however significant improvements in process are expected to reduce days sales outstanding during FY24.

The Company has a sales and support base in Mexico and is operating there both through partners and directly with a small team on the ground. In 2023 we established a subsidiary there and have put in place a somewhat greater resource and systematic approach to develop the market. With the second largest

economy in Latam, an historically strong currency and well-developed public and private hospital systems Mexico is an attractive place for IMEXHS to grow.

Our sales management teams have delivered strong and growing results and continue to develop the way they go about addressing the market opportunity. Despite the cost out project we have in fact significantly strengthened our software sales capability. The company continues to work on and improve underlying processes throughout the organisation which contribute to efficiency and allow the business to scale and grow – there is always more to do in this regard.

Our small Australia based team of directors and finance management liaise closely with the management team in Bogota and visit as appropriate. Despite the distance it is a joined-up organisation.

We appreciate the support and engagement of our shareholders and have sought to improve our communication. We believe we are on the way to creating a valuable business and are on the cusp of demonstrating that for all to see.

I want to thank my fellow directors for their engagement, contribution and diligence. Most importantly I want to thank our great team of people, ably led by our CEO, Dr German Arango, for their dedication and outstanding work.

I will now invite our CEO Dr German Arango to address the meeting and provide a reprise of 2023 and a look forward to 2024.

CEO’s Address

I am honoured to address you at this year's Annual General Meeting for IMEXHS Ltd.

As we reflect on the past year, 2023 marked a pivotal turning point for our company. Through a blend of strategic foresight and rigorous execution, we have not only achieved but also exceeded our key financial and operational goals, setting a robust foundation for sustained profitability and growth.

As most of you may know, we are one company with two businesses, Medical Imaging Software and Radiology Services.

We have successfully expanded our Software business into 18 countries, with more than 480 sites installed and, our Radiology services is now operating across 35 centers in Colombia.

2023 Highlights

Financial Growth: In terms of financial performance, we observed a significant 15% increase in revenue, reaching $19.7 million. More importantly, we achieved a positive cash flow and saw our underlying EBITDA rise to $0.4 million—an improvement of $0.5 million from the previous year. Our end-of-year cash balance strengthened to $2.4 million, a testament to our effective financial stewardship. The second half revenue increased by 42% on PCP, confirming the acceleration of our growth.

Annual Recurring Revenue (ARR): Our ARR soared to $25.0 million, marking a 27% increase from last year. This growth was propelled by our targeted efforts in both the Radiology and Software divisions, with respective ARR contributions of $14.5 million and $10.5 million.

Operational Highlights

Software Division: Our software solutions have been in high demand, underscored by several significant new contracts and renewals in the latter half of the year, which are poised to improve our revenues into 2024.

Radiology Services: We achieved a 100% success rate in meeting our ARR targets, reaffirming our leadership in providing cutting-edge outsourced imaging solutions.

Future Vision and Strategy: The past 15 months have been transformative as we developed and began rolling out our New Value Proposition (NVP). This initiative is bringing forward substantial enhancements in software capabilities, especially beneficial to large-scale hospital networks. These enhancements focus on improved service resilience, expedited implementation times, and reduced reliance on help desk support, all fortified by advanced AI and integration capabilities.

Our strategic roadmap for NVP is built on three pillars:

1. Service Excellence: Our unwavering commitment to setting industry benchmarks in customer support, training, and engagement remains a cornerstone of our strategy.

2. Innovation in Deployment: We are revolutionizing the speed of deployment, significantly reducing the time from initial contact to full operational status, thus delivering immediate value to our clients.

3. Advanced RIS-PACS Tools: We are enhancing our offerings with superior visualization capabilities, deeper AI integration, and comprehensive support tools that empower radiologists and improve productivity across our networks.

Plan and Outlook for 2024

The current year promises to be one of accelerated growth and increased profitability, as we continue to build on our strong end to 2023.

We have a robust pipeline of software opportunities and operational strategies aimed at enhancing efficiency and profitability, particularly within our radiology services.

Our sales and support teams have excelled, adapting our strategies to maximize market opportunities and achieve our software sales goals, especially with our expansion into the Mexican market. This strategic move is already meeting its revenue and new ARR goals and, now targeting large public and private hospital networks.

In the front of Radiology Services, our strategy for 2024 is structured to enhance profitability while fortifying our market position. We aim to broaden our margin expansion through strategic pricing models and cost efficiencies that do not compromise our service quality. While we continue to explore opportunities for expansion, our strategic forecast suggests that we will likely consolidate and strengthen our presence within Colombia throughout 2024, ensuring that we solidify our leadership and deliver enhanced value before we consider broadening our geographical footprint.

As Doug has said, this AGM is a month earlier than we would normally hold it. We did so because of the opportunity to align with the need to hold a meeting to approve the placement to directors and hold the AGM at the same time. However, we have our 4C reporting next week and I am loath to provide a definitive update when we are in fact still refining the numbers. That said, I can confirm we have had a strong first quarter of revenue overall. Investment in our sales team is being rewarded and our software new sales continues to be on plan. Our software development program is hitting the planned milestones and recent deliverables have included meeting new ARR and revenue goals for the business. Beyond that you will have to wait until we release our 4C for Q1.

In March, following our announcement of the annual results for 2023, we successfully completed a capital raise through a placement of $1.25 million, drawing strong support from both new and existing institutional investors. These funds will further strengthen our balance sheet and facilitate our growth initiatives.

I extend my deepest gratitude to our dedicated team, loyal customers, supportive partners, and you, our shareholders, for your unwavering trust and support. Also to our very committed board of directors, in particular to our Chairman Doug Flynn for his exceptional ongoing support and dedication. Your commitment fuels our continuous drive to redefine the possibilities within the medical imaging and radiology sectors.

Thank you for your ongoing confidence in IMEXHS Ltd. We look forward to a future filled with innovative developments, sustainable growth, and substantial shareholder value.

==> picture [181 x 58] intentionally omitted <==

Annual General Meeting 23 April 2024

Board of Directors

==> picture [132 x 157] intentionally omitted <==

==> picture [131 x 157] intentionally omitted <==

==> picture [131 x 157] intentionally omitted <==

==> picture [132 x 157] intentionally omitted <==

Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director

IMEXHS LTD (ASX:IME) | AGM 23 April 2024

2

==> picture [720 x 405] intentionally omitted <==

----- Start of picture text -----

Registration & Voting
2. Click view and register 3. Record your vote. Once
1. Log in or register at:
https://investor.automic.com.au/#/home your attendance for the you confirm it is lodged and
meeting final
To contact support:
Call 1300 816 159 or open live chat from the Investor Portal
----- End of picture text -----

Agenda 2024 AGM

==> picture [118 x 49] intentionally omitted <==

==> picture [382 x 169] intentionally omitted <==

1. Introductions

2. Chairman’s Address

3. CEO’s Address

4. Business of Meeting

5. Resolutions & Proxy Vote Results

4

==> picture [118 x 37] intentionally omitted <==

Chairman’s Address Doug Flynn

==> picture [118 x 37] intentionally omitted <==

CEO’s Address Dr German Arango

==> picture [118 x 49] intentionally omitted <==

One Company with two businesses aimed at democratising access to medical imaging expertise

Global footprint

==> picture [118 x 50] intentionally omitted <==

Software

18 countries; 485 sites

3,184 radiologists

28 distributors in 15 countries

Radiology

Colombia, Spain and Mexico

35 radiology centres

150+ in-house radiologists

8

==> picture [119 x 50] intentionally omitted <==

Sales Revenue Annual Recurring Revenue (ARR)[2]

$19.7m

$25.0m

Up 27% yoy

Up 15% yoy

Up 1% on a constant currency basis

Up 11% on a constant currency basis[1]

2H Revenue Closing cash Up 23% vs 1H FY23 $10.9m vs $1.9m at 31 $2.4m Up 42% yoy December 2022

Underlying EBITDA[3] Up $0.5m yoy $0.4m vs ($0.1m)

Debt vs $1.1m at 31 $1.3m December 2022

==> picture [720 x 234] intentionally omitted <==

----- Start of picture text -----

Business Highlights
•
The Company has demonstrated the scalability of the business across different geographies
with an attractive product and disruptive business model and now is focused on generating
positive earnings and cashflow.
•
Focus is on sales within Latin America and those product development projects that have a
path to profitability in the near term. Sales on plan and pipeline for both IMEXHS Cloud and
Enterprise radiology solutions remains robust.
•
Positive cashflow and Underlying EBITDA in FY23, supported by Revenue growth of 15%.
----- End of picture text -----

FY23 Revenue of $19.7m, 15% up on pcp FY23 Underlying EBITDA of $0.4m, up and 11% up on $0.5m vs pcp constant currency

Annualised

Recurring Revenue of $25.0m, up 27% vs pcp

Net operating cashflow of $2.6m before investing cashflows of $2.1m and net cash used in financing cashflows of $0.1m.

10

FY23 Operational Highlights

• Signed a new 5-year Software as a Service (SaaS) contract with Grupo Avidanti – Zentria. The contract is priced in USD, has a TCV of A$2.1m and is expected to contribute ~A$430,000 in ARR.

• Sales pipeline for both IMEXHS Cloud and Enterprise radiology solutions remains robust .

• IMEXHS Enterprise and IMEXHS Cloud finished the year with a total of 485 installations worldwide .

• A new subsidiary has been established in Mexico following progress made over the last two years to support partners and drive software sales directly .

• Software development program of Enterprise New Value Proposition remains on time and on budget with full release planned for Q4 2024.

• Two new radiology services contracts signed with Famisanar, Colombia’s fifth largest insurance provider, with a combined ARR of $1.6m. Both contracts are operational with IMEXHS Software installed.

• New radiology services contract signed with Grupo Avidanti. ARR of ~$1.0m expected by the end of 2024.

• Signed a 2-year radiology services contract with Colombia’s National Police force with ARR of $1.6m. IMEXHS Enterprise has been installed.

• Signed a 3-year radiology services contract San Carlos Hospital foundation with ARR of $530,000. IMEXHS Cloud has been installed.

• Detailed profitability analysis conducted for radiology customers and established minimum contribution margins.

11

Product and Software Updates

• Radiology Information System

• ➢ Achieved significant milestone - successfully formulated a novel architecture, technology stack, value proposition, and roadmap for an enhanced iteration of AQUILA (the RISPACS system).

• ➢ The initial Minimum Viable Prototype (MVP) has been developed and is set to be implemented at selected test sites during Q1 FY24.

• ➢ Set to evolve into core radiology product for specific segments in the future

• AQUILA v4.2 Updates

• ➢ Several stability and performance improvements

==> picture [118 x 49] intentionally omitted <==

• Universal Viewer v6.2 Enhancements

• ➢ Hanging protocols customisation tool feature, to improve radiologists’ experience.

• ➢ Integration and configuration of the Viewer and PACS v5.29 with a pathology focused RIS

• ➢ Updated the complete front-end version to Angular 14, so the viewer is ready for the latest improvements in functionality

• IMEXHS Patient Portal v3.1.0 Improvements

• ➢ Design and execution of the integration process with the new RIS. Support for utilization of anonymized studies.

• ➢ Notable modifications to seamlessly incorporate Single Sign-On (SSO) functionality with RIS.

• ➢ Backend enhancements have been made to facilitate the provision of a multi-tenant experience.

13

Focus for FY24

Software

Radiology Services

• 1) Rolling out New Value Proposition

• Enhanced digital security

• ○ Service levels ○ Integrated AI

• ○ Unique tools for Radiologist

• ➢ Targeted towards Enterprise level Ideal Client Profile

• ➢ Develop and imbed software sales capability in hard currency economies – Mexico and Central America

• 1) Margin expansion

• 2) Focus and growth in Ideal Client Profile

• 3) Tighten working capital management

• 4) Likely remain within Colombia in 2024

• 2) Drive and accelerate strong sales growth in 2024

• 3) Achieving solid renewal price increases going into 2024

14

FY24 Outlook

Key drivers for revenue and earnings growth:

• Revenue of $24.0 – $27.0m (22% – 37% up vs FY23)

• Underlying EBITDA of $1.5 - $3.5m (up vs $0.4m in FY23)

• Operating Cash flow further improved for FY24

• Annualised Recurring Revenue recently contracted and contracted but not yet billing.

• Current pipeline of opportunities.

• Further opportunities anticipated as the New Value Proposition Software is rolled out for Enterprise customers.

• Improvement in Radiology Services margin.

1. Underlying EBITDA excludes the impact of FX, share based payments and impairment charges.

15

==> picture [118 x 37] intentionally omitted <==

Business of Meeting

==> picture [118 x 37] intentionally omitted <==

Resolutions & Proxy Vote Results

Financial Report

To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2023.

Q&A

Resolution 1: Remuneration Report

“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2023 as disclosed in the Company’s Annual Report be adopted.”

==> picture [318 x 158] intentionally omitted <==

----- Start of picture text -----

Proxy votes
For Against Open
5,642,468 58,267 44,644
98.21% 1.01% 0.78%
----- End of picture text -----

Resolution 2: Re-election of Director – Dr Douglas Lingard

“That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.4 and 14.5, and for all other purposes, Dr Douglas Lingard, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
7,404,533 55,700 1,675,184
81.05% 0.61% 18.34%
----- End of picture text -----

Resolution 3: Re-election of Director – Mr Damian Banks

“That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.4 and 14.5, and for all other purposes, Mr Damian Banks, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
9,059,573 55,700 20,144
99.17% 0.61% 0.22%
----- End of picture text -----

Resolution 4: Grant of Options to the Chief Executive Officer

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 113,571 Options to the Managing Director & CEO, Dr German Arango, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,365,063 1,335,873 44,443
75.98% 23.25% 0.77%
----- End of picture text -----

Resolution 5: Grant of Options to Non-Executive Director Mr Damian Banks

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 27,945 Options to Non-Executive Director, Mr Damian Banks, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,315,063 1,385,873 44,443
75.10% 24.12% 0.77%
----- End of picture text -----

Resolution 6: Grant of Options to Non-Executive Director Mr Douglas Flynn

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 55,890 Options to Non-Executive Director, Mr Douglas Flynn, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,315,063 1,385,873 44,443
75.10% 24.12% 0.77%
----- End of picture text -----

Resolution 7: Grant of Options to Non-Executive Director Dr Doug Lingard

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 27,945 Options to Non-Executive Director, Dr Doug Lingard, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,315,063 1,385,873 44,443
58.31% 18.73% 0.60%
----- End of picture text -----

Resolution 8: Grant of Options to Non-Executive Director Mr Carlos Palacio

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 27,945 Options to Non-Executive Director, Mr Carlos Palacio, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [318 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,315,063 1,385,873 44,443
75.10% 24.12% 0.77%
----- End of picture text -----

Resolution 9: Approval of 10% Share Placement Capacity

"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) ( 10% Share Placement Capacity ) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

For	Against	Open
9,070,447	20,326	44,644
99.29%	0.22%	0.49%

Resolution 10: Ratification of Prior Issue of Securities – Placement

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, the Shareholders ratify the issue on 15 March 2024 of a total of 2,272,728 fully paid ordinary shares in the Company at an issue price of $0.55 per share under a placement to sophisticated and institutional investors on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

For	Against	Open
6,682,350	22,367	44,644
99.01%	0.33%	0.66%

Resolution 11: Approval of Issue of Shares to Mr Douglas Flynn under the Conditional Placement

“That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 90,909 fully paid ordinary shares in the Company at $0.55 per fully paid ordinary share to DR & LC Flynn Nominees Pty Limited as trustee for the Flynn Super Fund, an entity controlled by Mr Douglas Flynn, on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

For	Against	Open
5,537,781	161,326	44,232
96.42%	2.81%	0.77%

Resolution 12: Approval of Issue of Shares to Mr Carlos Palacio under the Conditional Placement

“That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 90,909 fully paid ordinary shares in the Company at $0.55 per fully paid ordinary share to Rio Negro Pty Ltd as trustee for the Medallo Trust, an entity controlled by Mr Carlos Palacio, on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
5,537,781 161,326 44,232
96.42% 2.81% 0.77%
----- End of picture text -----

Resolution 13: Approval of Issue of Shares to Mr Douglas Lingard under the Conditional Placement

==> picture [89 x 37] intentionally omitted <==

“That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 90,909 fully paid ordinary shares in the Company at $0.55 per fully paid ordinary share to Ilewise Pty Ltd as trustee for the Lingard Family Trust, an entity controlled by Dr Douglas Lingard, on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
5,537,781 161,326 44,232
74.85% 2.18% 0.60%
----- End of picture text -----

Resolution 14: Approval of Issue of Shares to Mr Damian Banks under the Conditional Placement

“That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 90,909 fully paid ordinary shares in the Company at $0.55 per fully paid ordinary share to HSBC Custody Nominees (Australia) Limited held as custodian for Damisuper Pty Ltd as trustee for the DE and MA Banks Super Fund, an entity controlled by Mr Damian Banks, on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
5,537,781 161,326 44,232
96.42% 2.81% 0.77%
----- End of picture text -----

Resolution 15: Approval of Issue of Shares to Dr German Arango under the Conditional Placement

“That approval be given for the purposes of ASX Listing Rule 10.11 and for all other purposes, for the issue of 90,909 fully paid ordinary shares in the Company at $0.55 per fully paid ordinary share to Dr German Arango, on the terms and conditions set out in the Explanatory Memorandum.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
5,537,81 161,326 44,232
96.42% 2.81% 0.77%
----- End of picture text -----

Resolution 16: Issue of Shares in lieu of Payment of NonExecutive Director fees to Mr Damian Banks

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Damian Banks, in lieu of the payment of certain director fees payable to Mr Damian Banks under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
9,039,884 55,701 39,832
98.95% 0.61% 0.44%
----- End of picture text -----

Resolution 17: Issue of Shares in lieu of Payment of NonExecutive Director fees to Mr Douglas Flynn

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Douglas Flynn, in lieu of the payment of certain director fees payable to Mr Douglas Flynn under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
9,039,884 55,701 39,832
98.95% 0.61% 0.44%
----- End of picture text -----

Resolution 18: Issue of Shares in lieu of Payment of NonExecutive Director fees to Dr Douglas Lingard

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Dr Douglas Lingard, in lieu of the payment of certain director fees payable to Dr Douglas Lingard under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
7,384,844 55,701 1,694,872
80.84% 0.61% 18.55%
----- End of picture text -----

Resolution 19: Issue of Shares in lieu of Payment of NonExecutive Director fees to Mr Carlos Palacio

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the non-executive Director, Mr Carlos Palacio, in lieu of the payment of certain director fees payable to Mr Carlos Palacio under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
9,039,884 55,701 39,832
98.95% 0.61% 0.44%
----- End of picture text -----

Disclaimer

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information.

Past performance detailed in this presentation is given for illustrative purposes only and should not be relied upon as an indication of the Company’s views on its future financial performance or condition. Readers should note that past performance of the Company cannot be relied upon as an indicator of (and provides no guidance as to) future performance, including the future trading price of the Company’s shares, or the reasonableness of any forward looking statements, forecast financial information or other forecast. Actual results could differ materially from those referred to in the presentation.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.

All financial information in this presentation is in Australian Dollars ($ or AUD) unless otherwise stated.

38

Annual General Meeting 23 April 2024